Vestmark Advisory Solutions Inc. Has $7.27 Million Stock Position in Twist Bioscience Corporation $TWST

Vestmark Advisory Solutions Inc. increased its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 117.0% during the second quarter, HoldingsChannel reports. The fund owned 197,597 shares of the company’s stock after acquiring an additional 106,541 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Twist Bioscience were worth $7,270,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of TWST. GAMMA Investing LLC grew its position in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after purchasing an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the period. Bayforest Capital Ltd lifted its stake in shares of Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company’s stock valued at $191,000 after buying an additional 1,604 shares during the period. Vanguard Personalized Indexing Management LLC grew its position in Twist Bioscience by 8.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company’s stock worth $222,000 after buying an additional 469 shares in the last quarter. Finally, Hsbc Holdings PLC bought a new position in Twist Bioscience during the first quarter valued at about $228,000.

Twist Bioscience Stock Down 1.2%

Shares of NASDAQ:TWST opened at $30.27 on Friday. The company’s fifty day moving average is $29.33 and its 200-day moving average is $31.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a market capitalization of $1.83 billion, a PE ratio of -20.88 and a beta of 2.43.

Insider Activity

In other news, CEO Emily M. Leproust sold 31,379 shares of Twist Bioscience stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $986,555.76. Following the completion of the transaction, the chief executive officer owned 738,809 shares in the company, valued at approximately $23,228,154.96. The trade was a 4.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Adam Laponis sold 5,875 shares of the stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $189,116.25. Following the sale, the chief financial officer owned 97,042 shares in the company, valued at approximately $3,123,781.98. This trade represents a 5.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 122,865 shares of company stock valued at $3,879,926 in the last ninety days. 3.01% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TWST. Barclays reduced their price objective on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd. Stephens started coverage on shares of Twist Bioscience in a research note on Monday. They set an “overweight” rating and a $41.00 price target on the stock. Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Finally, Evercore ISI decreased their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $47.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.